Human Fas Ligand / TNFSF6 Protein, His Tag, premium grade
分子别名(Synonym)
FASLG, ALPS1B, APT1LG1, CD178, CD95L, FASL, TNFSF6
表达区间及表达系统(Source)
Human Fas Ligand, His Tag, premium grade (FAL-H5241) is expressed from human 293 cells (HEK293). It contains AA Pro 134 - Leu 281 (Accession # AAH17502.1).
Predicted N-terminus: His
该产品经由我们严格的质量控制体系生产而成,包含无菌和内毒素检测等全面测试项目。我们已对产品性能进行严谨验证,并针对细胞培养用途及临床前研究阶段的其他应用完成相容性测试。当您准备进入后期临床阶段时,我们还提供定制化GMP蛋白质服务,可根据您的需求定制开发符合细胞治疗产品生产所需的原材料及辅料标准、同时满足您特定要求的GMP级别产品。
蛋白结构(Molecular Characterization)

This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 18.8 kDa. The protein migrates as 25-33 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
内毒素(Endotoxin)
Less than 0.1 EU per μg by the LAL method / rFC method.
无菌(Sterility)
Negative
支原体(Mycoplasma)
Negative
纯度(Purity)
>90% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
制剂(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

背景介绍
Fas配体(亦称FasL、CD178、CD95L或TNFSF6)是一种属于肿瘤坏死因子(TNF)超家族的同源三聚体II型跨膜蛋白。当其与受体结合时,可诱导细胞凋亡。Fas配体与受体的相互作用在免疫系统调控和癌症进展中具有重要作用。成熟的人源Fas配体由179个氨基酸的胞外结构域、22个氨基酸的跨膜区以及80个氨基酸的胞内结构域构成。在胞外结构域中,人源Fas配体与小鼠、大鼠的氨基酸序列同源性分别达81%和78%。由Fas-Fas配体结合触发的细胞凋亡在免疫系统调节中发挥基础性作用,其功能包括:维持T细胞稳态、调控细胞毒性T细胞活性、建立免疫豁免、维持母胎耐受、介导肿瘤反噬效应。Fas介导的凋亡途径缺陷可能导致肿瘤发生及现有肿瘤产生耐药性。Fas的种系突变与自身免疫性淋巴增殖综合征(ALPS)——一种儿童期凋亡功能障碍性疾病——密切相关。
关键字: Fas Ligand;Fas Ligand蛋白;TNFSF6重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group(股票代码:301080)是成立于2010年的跨国生物科技公司,是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球,横跨亚洲、北美洲、欧洲,在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家,与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。